ViralClear Announces Formation of Its Scientific Advisory Board
July 20 2020 - 1:50PM
- BioSig Subsidiary Enlists Seasoned Professionals in
Emerging Infectious Diseases and Regulatory Development to Its
Advisory Board
- ViralClear Pharmaceuticals is Currently in Phase II
Trials with Its Lead Asset Merimepodib in the Fight
Against COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”) subsidiary, ViralClear Pharmaceuticals, Inc.
(ViralClear), today announced the formation of its Scientific
Advisory Board (SAB). The SAB will review all aspects of drug
discovery and development and will advise the company on its
mission to control emerging infections and viral diseases of
special interest including COVID-19.
Initially, the external advisors of the SAB will consist of
Robin Robinson, Ph.D., the former Head of Biomedical Advanced
Research and Development Authority (BARDA), and J. Paul Waymack,
M.D., ScD, formerly of the Food and Drug Administration (FDA).
Dr. Robinson, who serves currently as the Chief Scientific
Officer for RenovaCare, Inc. (RCAR), brings extensive experience in
the development of vaccines and pharmaceutical products from
discovery and early development through advanced development
towards regulatory approval. Thirty-eight (38) products supported
by BARDA during his tenure at BARDA (2004-2016) were approved,
licensed, or cleared by the FDA.
Dr. Waymack is a former FDA medical officer, a former Associate
Professor of Medicine at the New Jersey School of Medicine and
Dentistry, and the former chairman of the board of directors and
chief medical officer of Kitov Pharma. He has had multiple patents
granted and over 100 scientific publications in medical journals
primarily related to the fields of immunology and infections.
During his career he has also successfully brought multiple drugs
and medical devices through clinical development to FDA
approval.
“The quality of the SAB members reflects the interest in
ViralClear’s assets, including merimepodib, for addressing the
current COVID-19 pandemic and other serious viral infectious
diseases that cause major economic disruptions” stated Jerome
Zeldis, MD, PhD, the acting Chief Medical Officer and Head of
ViralClear. “We are fortunate to be able to tap into their
collective wisdom.”
Dr. Waymack stated, “As society now faces its greatest
biological threat in over a century, it is critical that we develop
new therapies to treat this pandemic. Based upon in vitro data,
merimepodib appears to offer significant potential in treating
COVID-19 patients. I am therefore honored to be able to participate
in its development and to serve on ViralClear’s scientific advisory
board. I look forward to working with the talented individuals
serving on this board and with the company’s physicians and
scientists.”
It is expected that other experienced scientists and clinicians
will join the SAB over the next three to six months.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib and ViralClear
BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to
develop a novel pharmaceutical called merimepodib to treat patients
with COVID-19. Merimepodib is intended to be orally administered,
and has demonstrated broad-spectrum in vitro antiviral activity,
including strong activity against SARS-CoV-2 in cell cultures.
Merimepodib was previously in development as a treatment for
chronic hepatitis C and psoriasis by Vertex Pharmaceuticals
Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5
in phase 2) with over 400 subjects and patients and an extensive
preclinical safety package was completed. A manuscript titled, “The
IMPDH inhibitor merimepodib provided in combination with the
adenosine analogue remdesivir reduces SARS-CoV-2 replication to
undetectable levels in vitro”, was submitted to an online
peer-reviewed life sciences journal. This manuscript is authored by
Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T.
Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston
National Laboratory and Dr. Jerome Zeldis of ViralClear as a
corresponding author. This article highlights pre-clinical data
generated under contract with Galveston National Laboratory at The
University of Texas Medical Branch.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024